Status:
COMPLETED
Effect of Remimazolam on Postoperative Nausea and Vomiting
Lead Sponsor:
Inje University
Conditions:
Postoperative Nausea and Vomiting
Eligibility:
FEMALE
19-65 years
Phase:
NA
Brief Summary
The present trial is to study the effect of low dose remimazolam on postoperative nausea and vomiting (PONV) in patients at risks of PONV (women, postoperative use of opioid, nonsmokers) undergoing la...
Detailed Description
Postoperative nausea and vomiting (PONV) is a common complication in patients undergoing general anesthesia. It is reported that PONV is observed in 50% of patients 24 hours after general anesthesia a...
Eligibility Criteria
Inclusion
- women undergoing laparoscopic cholecystectomy under general anesthesia.
Exclusion
- moderate to severe liver dysfunction (total bilirubin ≧ 3.0 mg/dL / aspartate aminotransferase(AST) or alanine aminotransferase(ALT) ≧ 2.5 times more than normal range)
- moderate to severe renal dysfunction (serum creatinine ≧ 2.0 mg/dL / end-stage renal disease undergoing hemodialysis)
- tolerance to benzodiazepines
- hypersensitivity to anesthetic drugs (Benzodiazepines, Propofol, Remifentanil, Fentanyl citrate, Rocuronium bromide, Flumazenil)
- acute angle glaucoma
- alcohol dependence
- Galactose intolerance, Lactase deficiency, glucose-galactose malabsorption
- pregnant, breast feeding women
- BMI \>35 kg/m2
- uncontrolled diabetes mellitus
Key Trial Info
Start Date :
April 13 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 31 2024
Estimated Enrollment :
108 Patients enrolled
Trial Details
Trial ID
NCT05439057
Start Date
April 13 2022
End Date
October 31 2024
Last Update
June 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanggye Paik hospital
Seoul, South Korea